University of Turku has awarded Title of Docent to Sami Ventelä and Santosh Lamichhane
The University of Turku, Department of Clinical Medicine has awarded the Title of Docent (Adjunct Professor) in Otorhinolaryngology to Senior Research Fellow and Affiliated Group Leader, MD Sami Ventelä and Department of Life Technologies has awarded the Title of Docent (Adjunct Professor) in metabolomics to Academy of Finland Postdoctoral Researcher, Ph.D. Santosh Lamichhane.
Sami Ventelä
After graduating MD, in 2002, and PhD in 2003 from University of Turku he has started translational cancer career pathway that combines direct patient work with head and neck cancer patients and active research work in the field of cancer. He graduated specialist in otorhinolaryngology in 2010, after which he was a post-doctoral reseracher in Jukka Westermarck’s research group in Turku Bioscience Centre alongside with his concurrent patient work in University Hospital of Turku.
His research focuses on identifying head and cancer patients suffering from increased mortality and finding novel biomarkers suitable for clinical use that could improve the poor survival rate of these patients.
– Whereas recent advances in both surgical and oncological treatments have contributed increase in quality of life of head and neck cancer patients, they have resulted in only negligible improvements in patient survival. Therefore, the need for new treatment-guiding biomarkers in hospitals is particularly great in these cancers, in which we have not yet succeeded to reduce patient mortality, says Sami.
Santosh Lamichhane
After PhD in 2017 from Aarhus University, Denmark in the field of Food metabolomics he has carried out postdoctoral research in Systems medicine group headed by Dr. Matej Oresic in Turku Bioscience Centre. His research focuses on metabolomics applications in biomedical research and related integrative bioinformatics.
-Metabolomics is an exciting and evolving research tool, which involves the study of small molecules in biological system. Metabolomics based study can shed light on mechanisms of diseases as well as provide useful diagnostic, prognostic and risk factor biomarkers, says Lamichhane.
Recent Posts
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026